A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)
Completed · Phase 3 · NCT03785366
Conditions: Women at Risk for Pregnancy
At a glance
- Research payments reported, 2025
- $8,276
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 41
About the trial
- Sponsor
- Sebela Women's Health Inc. (with Synteract, Inc.)
- Tested
- VeraCept (drug), ParaGard (drug)
- Dates
- Started 2018-12-17; completion 2024-08-01
- Results posted
- Yes
to Assess the Pharmacokinetic Properties of VeraCept® Intrauterine Contraceptive vs ParaGard® in Healthy, Post- Menarcheal Women
From ClinicalTrials.gov, last updated 2025-08-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sebela Women's Health Inc. reported $8,276 in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dunsmoor-Su $6,169
- Ohsu Hospital and Clinics, OR $2,107
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.